NEMIS Technologies closes CHF 7.75 million series A funding round

NEMIS Technologies Ltd., amongst the Top 15 Swiss Biotech Startups of 2021, announces the closing of a CHF 7.75 million Series A financing round with the participation of both institutional and private investors. NEMIS specializes in fast, easy-to-use, affordable and reliable on-site pathogen detection solutions. The company will use the investment to scale up its production, accelerate its ongoing international expansion, boost product development and relocate to new laboratory and office facilities in Au, ZH, Switzerland.

Arnaud Muller, CEO NEMIS, stated: "Following the great care and dedication of our team over the past year to rapidly industrialize and scale our production, the capital raised will enable us to accelerate our expansion in Europe and overseas. We also have the means to accelerate the development of additional diagnostic test kits and methods to further improve our offering, strengthen our organization in a targeted manner and to reach profitable growth. This would not be possible without the great trust from our partners and investors, for which we are very grateful."

Roger Meier, the Chairman of the Board, added, "In just three years, NEMIS has transformed itself from an interesting start-up into a very dynamic and promising growth company with a value proposition that serves a rapidly growing need in an almost optimal way. We are very pleased that we were able to inspire different types of investors - from the extraordinary successful company leader and entrepreneur to the international highly specialized, renown Foodtech fund, who will accompany us on our further journey. With gratitude and confidence, we look forward to creating great benefit for our stakeholders."